Цитата:
Сообщение от ZhaStas
Сильно смутила фраза:
"Number one, non-ACS patients represent the vast majority of coronary disease patients in the US, and number two, in patients who do not have ACS, it's very unclear that any of them should be getting PCI at all. The COURAGE trial, for example, suggested that PCI is no better than medical therapy in improving survival in patients who have stable angina. And then there are patients who don't even have angina, who have CAD but no symptoms, and certainly we don't think PCI helps those patients either. So if there is more PCI happening, and more costs associated with PCI, and most of those are occurring in a population that's not getting any survival benefit or quality-of-life benefit out of it, that is what's troubling."
|
А что смутило? "a population
that's not getting any survival benefit" относится к patients who have stable angina и patients who don't even have angina, who have CAD but no symptoms. А "a population that's not getting any
quality-of-life benefit" только к patients who don't even have angina, who have CAD but no symptoms. Или я неправильно поняла суть вопроса?